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1. Introduction
Japanese encephalitis (JE) is the most common epidemic viral encephalitis in the world to‐
day. It is estimated that the JE virus causes at least 50,000 cases of clinical diseases each year
resulting in about 10,000 deaths and 15,000 cases of long-term, neuro-psychiatric sequelae. In
recent decades, outbreaks of JE have occurred in several previously non-endemic areas. Near‐
ly 3 billion people live in JE-endemic regions, where more than 70 million children are born
each year. For many years, only an inactivated JE vaccine made from infected mouse brain
was licensed for use by residents and travelers. However, this vaccine proved to have an
unacceptable levels of adverse safety events. Recently a safe and efficacious single-dose, live-
attenuated vaccine (SA14-14-2) produced in China has become available to many Asian coun‐
tries. It was higher immunogenicity, fewer doses of vaccination, less side reaction and cheaper
than that of the world wide used mouse brain inactivated vaccine. Since it was licensed in
1989, the vaccine has been used in more than 300 million children with no vaccine-associat‐
ed encephalitis case ever reported. Currently the vaccine is produced using specific patho‐
gen free (SPF) hamster kidney cell (PHKC) in accordance with WHO technical specifications
[47]. This paper reviews the development of the SA14-14-2 vaccine and its characteristics.
1.1. Development of SA14-14-2 attenuated JE live vaccine
1.1.1. History of selecting attenuated vaccine virus SA14-14-2 strain
The vaccine virus strain SA14-14-2 was derived from a wild-type Japanese encephalitis (JE)
virus SA14 isolated from pool of Culex pipiens mosquito larvae in Xi’an, China. Attenuation
was accomplished by serial passages of the SA14 virus in primary hamster kidney (PHK) cell
culture at 36 - 37℃. After 100 passages in PHK cells, followed by 3 times of plaque cloning,
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one clone 12-1-7 was selected from 36 plaque clones, which exhibited lower degree of viru‐
lence,LD50>6.0log10TCID50 [25]. However its neuroattenuation was unstable and reverted to
the virulence of parental SA14 after 1-2 mouse brain or several PHK cell passages [54]. The
12-1-7 clone was further plaque purified for 3 times and another 37 plaque clones were obtained.
However those clones still showed unstable after 1-2 mouse brain passages. Then another
method was performed for further attenuation. One selected virus clone (SA14-17-4) was
peripherally passaged in non-neural tissues (spleen and skin) of mice followed by several times
of plaque purification, which resulted in selecting an avirulent and highly stable virus clone,
SA14-9-7. However, after human clinical trial, the SA14-9-7 strain showed low immunogenic‐
ity in vaccinated children (seroconversion <10%[54]). In order to promote immunogenicity,
the SA14-9-7 virus was orally passaged six times in hamster, spleens harvested for two pla‐
que purifications. One selected clone, SA14-5-3, demonstrated higher seroconversion rates in
vaccinated children, 86.2% in JE endemic area[54] and 62%in JE non-endemic area[2].The
SA14-5-3 strain has been licensed for vaccine production and about five million children were
vaccinated. SA14-5-3 vaccine was demonstrated to be safe but low protective efficacy, 64 - 93%
in humans in the clinical trial involving 400 thousand children [54].
Methods Names
SA 14 virus isolated from pool of Culex pipiens larvae by 11 passages in
mouse brain (SA14)
100 serial passages in PHK cells, followed by three plaque purifications in
PCE cells
(SA14 clone
12-1-7)
Two plaque purifications in PCE cells (SA14 clone 17-4)
One intraperitoneal passage in mice; harvesting of spleen for one plaque
purification in PCE cells (SA14 clone 2)
Three plaque purifications in PCE cells (SA14 clone2-1-9)
One passage in mice, harvesting of skin and subcutaneous tissue for one
plaque purification in PCE cells (SA14 clone 9-7)
Six oral passages in hamsters; harvesting of spleens for two plaque
purifications in PHK cells (SA14 clone 5-3)
Five passages in suckling mice; harvesting of skin and subcutaneous tissue
for two plaque purifications in PHK cells
(SA14 clone
14-2)*
Table 1. Attenuation history of Japanese encephalitis SA14-14-2 virus strainPCE: primary chick embryo; PHK: primary
hamster kidney. * The notation SA14 clone 14-2 is abbreviated to SA14-14-2
To further promote immunogenicity, the SA14-5-3 virus was serially passaged by the subcu‐
taneous route in suckling mice, using injected site skin and local lymph nodes for the subse‐
quent passage materials. After cloning twice in PHK cells, the SA14-14-2 clone was selected
[55]. This strain was equally attenuated compared to the SA14-5-3 but more immunogenic in
mice, guinea-pigs, and pigs [55]. In human trials SA14-14-2 produced seroconversion rates
greater than 90% in JE non-immune subjects living in JE non-endemic region [2]. Besides,
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Eckels et al. [7] adapted the SA14-14-2 virus to primary canine kidney cell cultures for 9
passages, SA14-14-2 PDK virus，which showed avirulent in mice and monkeys. However,
SA14-14-2 PDK virus resulted in an unacceptably low neutralizing antibody response - 40%
seroconversion rate - in childen in China [60]. The passage history is shown in Table1 and the
characteristics of the various attenuated virus derivatives are shown in Table2 and 3.
Virus/clones Neurovirulence after different mouse brain passages
0 1 2 3 4 5
SA14 6.5a (-)b 7.7(8.0) - - - -
SA14-12-1-7 0(5.5) ≥1.5(-) 6.33(-) - - -
SA14-12-1-1 <0.0(7.5) 2.50(6.5) - 6.00(7.00) - -
SA14-9-4-2 <0.0(6.5) ≤1.83(6.0) - 7.17/6.50 - -
SA14-17-4 0(-) ≥4.5(≥4.5) - - - -
SA14-2 0(-) 0(-) <1.0(5.0) 1.42(6.5) 1.0(6.0) <1.0(6.5)
SA14-2-1-9 0(4.5) 0(≥6.5) 0(5.0) <1.0(5.5) 1.30(≥7.5) ≥5.12(7.5)
SA14-9-7 0(6.0) 0(4.0) 0(4.0) 0(5.0) 0(4.0) 0(4.5)
SA14-5-3 0(5.0) 0(5.5) 0.62(4.0) 0(4.75) 0.58(6.5) 2.21(6.5)
SA14-14-2 0(7.0) 1.0(-) 0.58(-) 0.67(-) 0.57(-) ≤2.0(-)
Table 2. Neuroattenuation and its stability (reversibility) of various derivatives of attenuated strains from SA14 virus
strainsa., Intracereble ( i.c.) inoculation tested in weanling mice, log10LD50/0.03ml b., log10TCID50/0.2ml - not
determined
Virus/
clones
Neurovirulencea Reversibilityb Immunogenicityc
Dose
(log10pfu/ml)
log10LD50/ml or No.dead/
no.tested
SA14 8.78 8.50 ND ND
SA14-12-1-7 7.7d 1.65 + ND
SA14-9-7 6.70d 0/10 - Low
SA14-5-3 6.47 0/10 - Moderate
SA14-14-2 7.17 0/10 - High
SA14-14-2
PDK
6.25 0/10 ND Moderate
Table 3. Summary of the characteristics of various derivatives of attenuated strains from SA14 virus strainND not
determined a) i.c. inoculation tested in weanling mice b) Reversion to neurovirulence of the parental SA14 virus in mice
model: +, neuroreversion after one suckling mice or 1-2 weanling mice i.c. passages; -, no neuroreversion after mice i.c.
passages. c) Neutralizing antibody seroconversion in humans: low, <10%; moderate, 40%~60%; high, ≥90%. d)
log10TCID50/ml
1.2. Clinical studies
Vaccine safety has been evaluated in several small-scale studies and in two large-scale stud‐
ies in China. Studies of 588,512 children aged between 1 and 15 years inoculated with vac‐
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cine from one manufacturer [35] and of 60000 children given vaccine from another manufacturer
[15] reported no cases of temporally associated encephalitis. The most common adverse effect
associated with vaccination was fever, which was reported in less than 0.2% of vaccinated
children, with lower rates for rash and other systemic symptoms.
Daily examination of 867 vaccinated children for fever (>38℃) disclosed low rates with on‐
set distributed evenly over the 21-day observation period, without clustering as might have
been expected if onset were associated with a specific incubation period. Temperature eleva‐
tions were limited to a single day in most cases.
A block-randomized coherent study of 13,266 vaccinated and 12,951 nonvaccinated children
followed prospectively for 30 days has shown that no cases of encephalitis or meningitis were
detected in either groups, and rates of fever, allergic, respiratory symptoms were similar in
the two groups [33]. Moreover no case of encephalitis associated with the live vaccine has been
reported so far from the large scale vaccination in other areas of China [66] and in countries
outside China [38, 4].The vaccine is well tolerated in subjects as young as 8 months.
The immunogenicity and protection efficacy in humans have been studied several times in
China and outside China. Neutralizing antibody were produced in 85%~100% of non-im‐
mune subjects studied in China [2, 58, 20, 64] and 98%, 92% and 95% studied in Korea [38],
Philiphines [12] and Thailand [6], respectively after a single dose of vaccination. Several efficacy
trials of SA14-14-2 vaccine in China from 1988 to 1999 in 1 to 10 year-old children have
consistently yielded high protection rates, above 95%,[66, 5, 43]. One study in Guizhou prov‐
ince [67] and another in Anhui province [66] have shown the protection efficacy persisted for
at least 11 and 5 years respectively following an immunization schedule of one primary dose
at one age and one booster dose at two ages. Case-control study for evaluation the efficacy of
SA14-14-2 vaccine has been studied. A case control study conducted in 1993 in Sichuan province,
China in children <15 years measured vaccine effectiveness of routinely delivered SA14-14-2
vaccine at 80% for a single-dose and 97.5% for a two-dose given at a one year interval [14]. In
1999, the SA14-14-2 vaccine was given as a single dose to over 220000 residents of the Terai
region of Nepal in an effort to reduce the impact of an emerging epidemic of JE. A case-
control study demonstrated 99.12% efficacy [4] followed by a 5-year efficacy of 96% [41]. In
2000, a case-control study in Chongqing city, China found a 93% efficacy after one dose
vaccination [42]. Besides, Kumar [23] reported a case control study in India, where 9.3 mil‐
lion children were immunized with SA14-14-2 vaccine in 2007, demonstrated a 94.5% vac‐
cine efficacy after a single dose.
2. Phenotypic characteristic
2.1. In vitro phenotypic characteristics
SA14-14-2 attenuated virus replicates  well  in  primary hamster  kidney (PHK) cell,  C6/36
mosquito cells, continuous African green monkey kidney (Vero) cells, Rhesus monkey kid‐
ney (LLC-MK2) cells and baby hamster kidney (BHK21) cell lines. SA14-14-2 virus showed
homogeneous small plaques (≤1mm) when grown in above - mentioned cells, while SA14
wild strain showed heterogeneous and larger plagues (2-3mm) [57][1].
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Many attenuated viruses are temperature-sensitive, often showing restricted growth in vi‐
tro at 39-40℃, some strains were even sensitive to 37°C. SA14-14-2 strain was not temperature-
sensitive, showing no reduction in infectivity at 37°C or 40°C. SA14-14-2 strain was also
thermostable  as  the  parental  SA14  virus.  In  liquid  status  reduction  of  virus  titer  was
3.5log10TCID50 after heated at 50℃ for 50 minutes and virus could be detected 4 hours after
further incubation at 50°C, a result similar to that observed with SA14 parent strain. SA14-14-2
was more thermostabe than the SA14-5-3 [57].
2.2. Ability of in vivo virus replication
Yu et al. [55] studied the replication ability of SA14-14-2 virus in young mice (2.5 weeks)
by subcutaneous（s.c.） inoculation followed by recovering virus from spleens and subcu‐
taneous tissues of the infected mice for 2 weeks post inoculation. In those mice infected with
the parent SA14 strain, viruses were recovered from the both tissues from day 4 to day 10
post infections, while those mice inoculated with SA14-14-2 strain, viruses were isolated in
both tissues as well but limited within a short period from day 2 to day 4 or day 6 post
infections (Table 4). Wu et al. [49] performed a similar study for recovering virus from brains
and sera of the infected mice. Mice that infected with as less as 2.7log10 pfu/mL of the parent
SA14 virus, high titers (≥6.0log10 pfu/mL) of virus was detected in the brains and low tit‐
ers (2.7 – 3.4log10 pfu/mL) in the sera, whereas mice inoculated with as high as 6.2log10 pfu/
mL of the SA14-14-2 ，, virus was neither detected in the brains nor in the sera of the mice.
Lee et al. [24] examined virus growth of SA14-14-2 live virus and the parent SA14 virus
strains in mice after i.p. inoculation. The results showed that SA14 virus was detected in
sera and in spleens with peak titers of 3.24log PFU/ml and 4.3 logPFU/g, respectively as
well  as brains with peak titer of  6.42logPFU/g.  On the other hand, SA14-14-2 virus was
detected only in the spleens with extremely low titer (1.7logPFU/ml) but not detected in the
sera and brains of all ten inoculated mice.
Virus strain Infected virus titer(log10 TCID50/mL)
Tissues
detected
Virus titers (log10TCID50/mL) by days after
inoculation
2 4 6 7 10 14-15
SA14-14-2 6.7
SC a
tissue 3.2 4.2 1.0 ND ND ND
spleen 4.2 4.2 0 ND ND ND
SA14 5.7 SC tissue ND 2.7 ND ≥4.2 0 0spleen ND 2.2 ND ≥4.2 ≥3.2 0
Table 4. In vivo replication of SA14-14-2 strain in mice. a Subcutaneous tissue
Further investigation for viremia induction of SA14-14-2 virus using guinea pigs animal model
has been studied by Liu et al [31]. Guinea pigs intraperitoneally (i.p.) injected with 4.0log10
pfu/mL of parent virus SA14 and other 4 JEV virulent strains induced viremia to virus titers
of 1.0-3.0log10 pfu/mL and lasted for 3 days post infection. However, the animals inoculated
with SA14-14-2 strain containing virus titer equal to that of the virulent strains, no viremia
was detected from day 1 to day 10 post inoculation (Table 5)
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Besides,  a  viremia  clinical  study in  India  has  demonstrated the  absence  of  any viremia
activity in adult population up to 15 days after administration of a single dose of the live
JE SA14-14-2 vaccine.
Virus strain Animal No.
Viremia titer by day after inoculation
(log10 pfu/mL)
1 3 5 7 10
P3
No.1 2.04 2.18 0 ND ND
No.2 2.08 2.59 0 ND ND
No.3 2.23 2.56 0 ND ND
No.4 1.70 2.21 0 ND ND
02-41
No.1 1.00 1.78 0 0 0
No.2 1.78 1.70 0 0 0
No.3 1.78 1.60 0 0 0
No.4 1.00 1.90 0 0 0
No.5 1.30 1.95 0 ND ND
HLJ02-144
No.1 1.90 1.30 0 0 0
No.2 2.00 1.00 0 0 0
No.3 1.95 1.48 0 0 0
No.4 1.95 1.48 0 0 0
No.5 2.48 ND ND ND ND
SA14
No.1 2.92 ND ND ND ND
No.2 2.41 2.85 0 0 0
No.3 2.94 3.40 0 0 0
No.4 2.53 3.00 0 0 0
No.5 3.02 ND ND ND ND
SA14-14-2
No.1 0 0 0 0 0
No.2 0 0 0 0 0
No.3 0 0 0 0 0
No.4 0 0 0 0 0
No.5 0 0 0 0 0
Table 5. Viremia in guinea pigs after i.p. inoculation with different JEV virus strains. ND, Not determined
These results indicated that growth of the attenuated live virus in vivo was significantly re‐
duced in contrast to the growth of parent SA14 virus, and SA14-14-2 strain showed a lack of
viremia and neuroinvasion.
2.3. Neuroattenuation phenotype
Mice and rhesus monkeys are highly susceptible to the wild virulent Japanese encephalitis
virus (JEV) inoculated by intracerebral route. Approximately 1~10 plaque forming unit (pfu)
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of the virus inoculated intracerebrally results in death. Mice are more susceptible than mon‐
key to JE virus following inoculation by the peripheral route. Rhesus monkeys show four
grades of response to the different attenuated JE viruses by i.c. inoculation [68]:
1. “death”, the inoculation with parental SA14 virus;
2. ”survival but showing neurological signs”, i.e. the inoculation of SA14 95th PHK cell
passage virus (SA14 HKC-95) ;
3. “survival, without showing neurological symptoms, but with fever” i.e. the inoculation
with SA14-12-1-7 virus ;
4. “healthy”, no fever, no symptom, no death, i.e. when the vaccine virus SA14-14-2 was
inoculated.
Neurovirulence of JE SA14-14-2 strain was tested using these animal models with virus tit‐
ers of 7.0~8.0log10 pfu/ml. Weanling mice inoculated with the virus by i.c. or s.c. inoculation
did not cause death. SA14-14-2 was tested by standard intrathalamic and intraspinal combi‐
nation inoculation method in monkeys. Monkeys showed no mortality or morbidity and on‐
ly a minimal degree of CNS inflammation around the injection sites [30] (Table 6). Further,
neuropathogenicity was tested in immune- deficient or immune-suppressed animals, athy‐
mic nude mice or mice treated with cyclophosphamide. No deaths or histopathologic abnor‐
malities were observed after intraperitoneal or subcutaneous inoculation of a viral dose
greater than 107.0 TCID50/ml. Although cyclophosphamide increases susceptibility of mice
to virulent JE strains, immunosuppression with cyclophosphamide did not lead to encepha‐
litis in mice inoculated pheripherally with SA14-14-2 virus [56, 18]. The strain also did not
kill weanling hamsters by i.c. inoculations [55].
Virus
strain
(Virus titer,
pfu/ml)
Inoculation
route
Mice Rhesus Monkeys
Dilution Died/tested
Histopathological
score
(neuronal lesions)a
Died/tested
Histopathological
score
(neuronal lesions)ab
SA14
parent
(6.15×108)
IC 10-1 ND ND 2/2 2-4
10-4 8/8 2-4 0/1 2-3
10-5 ND ND 2/2 2-4
10-6 8/8 2-3 2/2 2-4
10-7 8/8 2-4 2/2 2-4
10-8 8/8 2-4 ND ND
SC 10-1 30/30 2-4(day 5) ND ND
SA14-14-2(
8×106)
IC 1:5 0/30 0-2 0/4 0-1
SC 1:5 0/30 0(1)c ND ND
Table 6. Comparative neurovirulence of attenuated SA14-14-2 and parent SA14 Japanese encephalitis viruses in 3-
week-old mice and adult rhesus monkeysIC, intracerebral; SC, subcutaneous. ND, Not determineda) 0, No lesion; 1,
≤5%; 2, 6-20%; 3, 21-50%; 4, >50% of neurons died.b) Inoculation in thalami bilaterally (each 0.5ml) and lumbar
spinal cord (0.2mL).c) One mouse showed a few dead nerve cells.
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2.4. phenotypic stabilities
2.4.1. Stability of plaque morphology
Small homogeneous plaque (≤1mm) morphology was retained through 8 -17 PHK cell pas‐
sages studied by Jia et al. [17]. As reported by Aihara, plaque-size phenotypes did not
change during plaque purification in BHK21 cells and propagation in C6/36 cell [1]. Eckels et
al. [7] showed that SA14-14-2 strain had a homogeneous small plaque morphology, with no
large plaques seen when passed 7 times in LLC-MK2 cells.
2.4.2. Stability of neuroattenuation
Wang et al. [44] studied neuroattenuation stability by serial passages the SA14-14-2 strain
from passage 8  to  passage 23 in PHK cells,  virulence was tested every 2-3  passages by
intracerebral or subcutaneous inoculation in mice (12 ~ 14g). None of the PHK-passaged
viruses containing virus doses of 8.0~9.0 log10TCID50 caused death in these mice. Jia et al.
[16] passed the SA14-14-2 virus in PHK cells for 17 passages, neurovirulence and neuroin‐
vasion were determined at the 8th, 15th, 17th passage. No animal showed illness at any the
passage level.
Eckels et al. [7] performed the neuroattenuation stability by serial passage the SA14-14-2 vi‐
rus in Beagle canine kidney cells for a total of 15 passages, the passage 15 virus was attenu‐
ated for young mice causing no symptoms or death by i.c. inoculation. Wang et al. [45]
passaged the SA14-14-2 HKC5 virus in primary dog fetal kidney cell cultures for 11 passag‐
es. Each of the passaged virus was tested for its pathogenicity in weanling mice, all the mice
survived by either i.c. or s.c. inoculation with a virus dose containing 7.5-8.0
log10TCID50/0.2ml. These results showed that over many passages of the SA14-14-2 virus in
PHK cells or primary dog kidney cells, neuroviruence reversed to the virulence of parental
SA14 was not observed.
Wu et al [49] studied on the stability of SA14-14-2 vaccine seed virus by i.c. passage in suck‐
ling mice, viruses recovered from the mice brain of passage 1 only caused a few weanling
mice death following i.c. inoculation with a high dose of 8.7 log10pfu/ml virus (LD50≥7.7
log10pfu), showing no reversion to the virulence of SA14 parent virus (i.c.LD50≥0.28
log10pfu).
Athymic nude mice (nu/nu) inoculated intra-peritoneally with 8.2log10TCID50/ml of
SA14-14-2 virus did not fall ill. Attempts to recover virus from brain, liver, spleen, kidney,
heart and lymph nodes were made over a period of 3 weeks. In three independent experi‐
ments viruses were recovered only in one experiment from brain at the 10th, 14th and 21st day
and kidney tissue at 6th day. Virus isolated from the brains on day 21st after intraperitoneal
inoculation, was enhanced once in PHK cell to a virus titers of 6.7-7.2 log10TCID50/ml and
then tested for neurovirulence and neuroinvasiveness in normal mice. Tests were repeated
three times and showed that the recovered viruses were avirulent to 10-12g mice by i.c. or
intraperitoneal inoculation, maintaining the attenuated phenotype as SA14-14-2 [56].
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Neuroattenuation after long-term cold storage has been studied. Fourteen lots of lyophilized
live JE vaccines manufactured year by year since 1987 were stored at low temperature
(-20℃). After 15 years, neurovirulence of the vaccine viruses were studied in year 2002. The
results showed that viruses in the all 14 lots were avirulent for i.c. inoculated mice. [22]
2.5. Growth characteristics and ability of transmission in mosquitoes
Mosquito infection and transmission with SA14-14-2 virus have been done using Culex tri‐
taeniorhynchus mosquitoes, the most important JEV vector species, by oral feeding with
meals containing the virus or intrathoracial(IT) inoculation with the virus. The mosquitoes
did not become infected by oral feeding with meals containing 6.06log10pfu/ml virus and on‐
ly one of the 34 groups (3.13%) of the infected mosquitoes became infected after feeding
with meals containing 6.18 log10pfu/ml virus, reaching a low virus titer of 1.24log10pfu/ml.
However, most of the mosquitoes (10 of 14 groups, 71.43%) became infected after feeding
meals containing 7.85log10pfu/ml of virulent JE virus strain Nakayama(Nak), reaching high‐
er titers of 3.33-4.79 log10pfu/ml (Table 7) [62]. The result indicated that SA14-14-2 virus is
restricted in its ability to infect and replicate in the Culex tritaeniorhychus mosquito vector.
Virus strain Meals containingvirus(log10pfu/ml)
No. groups
tested
Total number of
mosquitoes
tested
No. group Positive (%)
SA14-14-2
6.06 15(4-31)1 345(15-36)2 0(0%)
6.18 34(2-11) 573(10-39) 1(3.13%)(1.24)3
Nakayama 7.85 14(3-11) 215(11-26) 10(71.43%)(3.33-4.79)
Table 7. Growth of SA14-14-2 virus and wild virulent JEV Nak strain in Culex tritaeniorhynchus mosquitoes by oral
infections.
Mosquitoes were exposed to virus-containing meals for oral ingestion. Fully engorged mos‐
quitoes were then collected after a period of extrinsic incubation.
1. Times(days) of extrinsic incubation periods;
2. Numbers of mosquito per group;
3. Virus titers in the mosquito suspensions of the positive groups (log10pfu/ml)
However, virus could replicate at low level by intrathoracical (I.T.) inoculation of the Cx.tri‐
taeniorhynchus mosquitoes [62], reaching titers of 2.0~3.72 log10pfu/ml over 2~20 days after
inoculation. In contrast, mosquitoes IT infected with its parent SA14 virus exhibited higher
ability of replication, reaching titers of 3.0~4.85 log10pfu/ml over the same periods [10].
The ability of transmission by the IT infected mosquitoes was studied later. Two groups of
the mosquitoes were infected IT with SA14-14-2 virus, 8 days after infection one group of
infected mosquitoes was used to infect suckling mice by direct bite, another group of infect‐
ed mosquitoes was made in a suspension (M-1), in which the virus content was measured,
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and used to infect weanling mice by i.c. inoculation. In order to enhance the virus titer of the
mosquito suspension (M-1), it was passed once in BHK cells (M-1 C-1) and then infected
mice by i.c. and s.c. inoculation. The full E protein gene of the M-1 C-1 virus was sequenced
and compared to that of its parent SA14-14-2 virus. As shown in Table 8, none of the mice
died after bitten or i.c. inoculation with virus titers of 4.2 and 7.2 log10pfu/ml, and only one
nucleotide in the virus E protein gene changed resulting in one amino acid substitution
(E447 A→G) which was not reverse mutation. And the eight critical amino acids remained
unchanged. The similarity of the virus full E gene sequence compared to that of the parent
SA14 was 99.9% [34]. This result demonstrated that the SA14-14-2 virus is phenotypic and
genetic stable and could not be transmitted after mosquito passage.
Virusa Virus titer Virulence tested in
Suckling mice 2.5 weeks mice
E gene sequence
Pfu/ml bittenb ic ic sc mutation similarity
SA14-14-2 M-1 104.2 0/16c 0/16
M-1C-1 107.2 0/10 0/10 0/8d E-447
(A→G)
99.9%
Table 8. Virulence and E gene sequence of the SA14-14-2 virus after Culex tritaeniorhynchus mosquitoes IT passage. a
One intrathoracical passage (SA14-14-2 M-1) and one BHK-21 cell passage (M-1 C-1).b By the infected mosquitoes c
No. dead /no. testedd No. reversion/no. attenuating amino acidSC Subcutaneously
 
3. Genotypic characteristics
3.1. Gene sequence of SA14-14-2 compared to its parent SA14 and other attenuated
derivatives.
When the full-length gene sequence of SA14-14-2 was compared to parental SA14, 57-66 nu‐
cleotide substitutions were found to be scattered all over the genome except prM. These
coded for 24-31 amino acid substitutions, of which 8 were in E protein[1, 61] and were stud‐
ied to be the critical amino acid mutations involved in virus attenuation [3, 13] (Table 9).
Among the 8 substituted amino acids observed in SA14-14-2 virus, only 3 substitutions ap‐
peared in the unstable virus SA14-12-1-7; while those highly and stable strains, SA14-9-7,
SA14-5-3 and SA14-14-2 PDK viruses had 6 changes of the 8 amino acids [Ni H et al.,1994, 8].
Two of the 8 amino acid substitutions at position E-177 (T,Threonine→A,Alanine) and E-264
(Q, Glutamine→H, Histudine) were unique to SA14-14-2 virus [8] (Table 10). The contribu‐
tion of these two amino acid changes to the biological properties of SA14-14-2 virus requires
further study.
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Position SA14-14-2 SA14aa nt Zeng Aihara
C-65 292 S S L
E-107 1296 F F L
E-138 1389 K K E
E-176 1503 V V I
E-177 1506 A A T
E-264 1769 H H Q
E-279 1813 M M K
E-315 1921 V V A
E-334 1977 P S S
E-439 2293 R R K
NS1-292 3351 S S G
NS1-339 3493 M M R
NS1-351 3528 H H D
NS1-354 3539 K K N
NS1-392 3652 V V A
NS2B-63 4403 D D E
NS2B-65 4408 G G D
NS2B-87 4475 F L L
NS3-59 4782 V V M
NS3-73 4825 K K R
NS3-105 4921 G G A
NS3-343 5634 R W R
NS4A-27 6634 I T I
NS4B-106 7227 V V I
NS5-31 7768 G A A
NS5-45 7809 S R R
NS5-195 8261 I M M
NS5-386 8832 Y Y H
NS5-636 9593 H Q Q
NS5-671 9688 A A V
NS5-731 9898 G D D
NS5-759 9954 P A A
NS5-767 9978 V L L
Table 9. Comparison of amino acid differences between JE attenuated vaccine SA14-14-2 and its parent SA14 strain
reported by Aihare and Zeng
Sequences were reported by [1] and [61]
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3.2. Stability of gene sequence of SA14-14-2 virus strain
SA14-14-2 virus at PHK cells passage 8 (PHK8) was serially passed to PHK17 or given one i.c.
passage in suckling mouse (HKC8SM1). The E protein gene of the viruses was sequenced and
compared to that of SA14-14-2 PHK8 and parental SA14. At passage 17, all the 8 attenuating
amino acid residues in SA14-14-2 PHK8 were retained no change, while two new nucleotide
mutations were found at NT-1970 (T฀G), and NT-2169 (A฀G), which resulted in two ami‐
no acid changes at positions E-331 (S฀R) and E-398 (K฀E)( Table 11). The two substituted
amino acids, Arg(R) and Glu(E), were not the residues of parental SA14, Ser(S) and Lys(K),
this suggests that the two changes were not reverse mutation [9]. After one passage of the
PHK8 virus in suckling mouse brain (SA14-14-2 HK8SM1), 7 of the 8 amino acids remained
unchanged, one at E107 (F→L) was reverse mutation, while 3 other amino acid mutations
appeared at E-83, E-318 and E-327, which were not reverse mutations (Table 11).
Virus Mutation sites
107 138 176 177 264 279 315 439
SA14-14-2 PHK F K V A H M V R
SA14-12-1-7 F E V T Q K A R
SA14-9-7 F K V T Q M V R
SA14-5-3 F K V T Q M V R
SA14-14-2 PDK F K V T Q M V R
Parental SA14 L E I T Q K A K
Table 10. Comparison of the amino acid differences in the E protein gene of JE SA14-14-2 PHK vaccine virus with the
other attenuated derivatives and the parental SA14
Site SA14 V2
SA14-14-2
HKC8V2 HKC17V2 HKC8SM1
E-83 E E E Q
E-107 L F F L
E-138 E K K K
E-176 I V V V
E-177 T A A A
E-264 Q H H H
E-279 K M M M
E-315 A V V V
E-318 G G G D
E-327 S S S F
E-331 S S R S
E-398 K K E K
E-439 K R R R
Table 11. Substitutions of amino acid of SA14-14-2 strain after passage in PHK cell or suckling mice. HKC8V2, HKC 8
passages, vero cells 2 passages ;HKC17V2, HKC 17 passages, vero cells 2 passages ;HKC8SM1, HKC 8 passages, suckling
mice one i.c. passage
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Li et al. [27] and Gao et al.[11] performed similar studies by additional passage of the
SA14-14-2 vaccine seed virus (early passage) in PHK cell culture to passage 20 and passage
18, respectively. The E protein gene sequences of the various passaged viruses were se‐
quenced and compared to the original seed virus.The results demonstrated no reverse muta‐
tion of the 8 attenuating amino acids.
Xu et al [52] studied full-length sequence stability of the SA14-14-2 virus by passing the early
passages seed virus(PHK8) on PHK cells to passage 22 (PHKC22) and its full-length genome
was sequenced. By comparing the full sequences of the PHKC22 with the original primary seed
virus of SA14-14-2 in Genbank (D90195), the result showed that there were only 8 nucleo‐
tide differences (one in E, 5 in non-structure-region and 2 in 3’-NTR) leading to 4 amino acids
changed, which were not reverse mutations. The homology of the nucleotides and amino acids
between the viruses of passage 22 viruses and the primary seed virus in Genbank was 99.93%
and 99.88%, respectively (Table 12). These results demonstrated that the genotype of SA14-14-2
vaccine virus was very stable during multiple cell culture passages.
Position Nucleotide change Amino acid change
Nt Aa
2142 E-389 a→c D→N
3929 NS2a-69 t→c none
5634 NS3-343 t→a W→R
6634 NS4a-57 c→t T→I
7655 NS4b-130 g→t none
9593 NS5-639 g→t Q→H
10701(3’-NCR) -→g
10784(3’-NCR) t→c
Table 12. Nucleotide and amino acid changes in the PHK cells passage 22 compared to the sequence of SA14-14-2 in
Genbank (D90195)
4. Immunogenicity
4.1. Humoral immune response
Wills et al. [48] investigated the ability of SA14-14-2 (PHK) and other 4 attenuated vaccine
clones SA14-2-8, SA14-5-3, SA14-14-2 (PDK) to induce a humoral immune response in Balb/c
mice. The mice, 6-8 weeks old, were inoculated by intraperitoneal route with 103 and 106 pfu
of the live viruses. Mice were bled 14 and 28 days postinoculation. Anti-JE serum antibody
levels were measured using hemagglutination inhibition (HAI) and neutralization (N) tests.
The results demonstrated that the live SA14-14-2 (PHK) elicited good HAI and N responses
at dose of 103 and 106 pfu at 14 days postinoculation, with the 28-days sera showing no re‐
duction in N titer. In comparison, 106 pfu of the SA14-14-2 (PDK) virus evoked only a poor
N response by 14 days postinoculation and neutralizing antibody was not detectable with a
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dose of 103 pfu either 14 or 28 days postinoculation (titre ≤20). The two early vaccine clones
SA14-2-8 and SA14-5-3 both produced results very similar to SA14-14-2 (PDK) in terms of
HAI and N responses at the given dose (Table 13).
Lee et al. [24] reported that mice vaccinated with one dose of SA14-14-2 virus
(4.0log10pfu/ml) produced N antibody (titer 1:60), HAI antibody(22.2), complement fixation
(CF) antibody (11.2) and were protected against a lethal JEV i.c. challenge (90% protection).
Meanwhile, the anti-NS1(non-structural NS1) antibody was detected in sera of the vaccinat‐
ed mice, which may also be responsible for the protection.
Virus strains
Titre at day 14 for dose (Log10 pfu) Titre at day 28 for dose (Log10 pfu)
3 6 3 6
N HAI N HAI N HAI N HAI
SA14-14-2(PHK) 320 320 640 80 320 NT 640 320
SA14-14-2(PDK) <20 40 80 320 <20 160 80 NT
SA14-2-8 80 NT 160 NT 160 NT 160 NT
SA14-5-3 40 NT 80 NT 160 NT 160 NT
Table 13. Humoral immune responses (N and HAI) derived from Babl/c mice inoculated with attenuated vaccine
strains. Note: N, neutralization titre, taken as the highest dilution of serum to neutralize 50% of plaque numbers of
homologous virus;HAI, Haemagglutination inhibition titre, taken as the highest dilution of serum to inhibit 4 HA units
of homologous virus;NT, not tested.
4.2. Protection efficacy
Several studies have demonstrated that SA14-14-2 live vaccine induced high and broad pro‐
tection against challenge by various JEV virulent strains in mice. Wang et al. [46] performed
a study comparing the protective efficacy of 3 kinds of JE vaccine, the SA14-14-2 attenuated
vaccine, the PHK derived P3 inactivated Vaccine (iPHKV) and the mouse brain purified in‐
activated Nak vaccine (MBV) in mice by i.p. inoculation with one dose of live vaccine, or 2
doses of the 2 kinds of inactivated vaccines respectively followed by i.p. challenge with 2
virulent JEV P3 and Nak strains. The results indicated that despite levels of neutralizing an‐
tibodies (N) developed by the vaccination with live vaccine and MBV were equal at the day
of pre-challenge, mice receiving the live vaccine were protected against the 2 challenging
strains at higher rates than mice receiving the 2 inactivated vaccines (Table 14). Yu et al.[59]
compared the immunogenicity of the SA14-14-2 live vaccine and iPHKV in mice by i.p. vac‐
cination followed by i.p. challenge with 14 wild strains isolated from different areas and
years in China. The results indicated that live vaccine induced higher and broader protec‐
tion levels than that induced by the iPHKV. In another study, Jia et al. [21] demonstrated
that mice s.c. inoculated with a single dose of 34 or 340 pfu/mL SA14-14-2 virus, mice were
protected (80-100%) against i.p. challenge of the 22 JEV strains (11 isolated in China and the
other 11 from Thailand, Vietnam, Indonesia, India, Philippines and Japan).
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Vaccine N titers at pre-challenge
against
Protection against
P3 Nak
P3 Nak i.p. i.c. i.p. i.c.
SA14-14-2 20a 40 10/10b 8/10 10/10 4/10
iPHKV P3 10 5 7/10 ND 5/10 ND
MBV(Nak) 20 40 8/10 3/10 4/10 1/10
Control ND ND 2/10 1/10 2/10 3/14
Table 14. Protection of three kinds of JE vaccine in mice. Note: ND, Not determineda) Reciprocal of the highest
dilution of serum that resulted in 50% reduction of plaque numbers.b) Number surviving challenge/number
challenged i.p. intraperitoneally
No. Challenge
Virus strain
Genotype Dose (pfu)
2340 234 23 Control Challenge virus
dose (log10LD50)
1 SH-53 I 10/10a 10/10 9/10 2/10 3.58
2 SH-101 I 10/10 10/10 10/10 2/10 3.17
3 LN02-102 I 10/10 8/10 4/10 1/10 3.84
4 SH03-127 I 10/10 8/10 7/10 1/10 3.71
5 HN04-11 I 10/10 10/10 5/10 2/10 2.75
6 SC04-17 I 10/10 9/10 10/10 2/10 4.00
7 SH05-24 I 10/10 9/10 4/10 1/10 3.77
8 02-29 III 10/10 10/10 7/10 2/10 3.50
9 02-41 III 10/10 10/10 6/10 2/10 4.50
10 HLJ02-134 III 9/9 10/10 6/10 2/10 2.88
11 HLJ02-144 III 10/10 8/10 4/10 0/10 3.00
12 DL04-06 III 10/10 9/10 9/10 2/10 3.24
13 P3 III 9/10 9/10 9/10 1/10 3.78
14 SA14 III 9/10 9/10 9/10 1/10 3.65
15 SA4 III 10/10 10/10 4/10 2/10 3.42
16 KT III 10/10 9/10 5/10 1/10 3.31
Table 15. Protection efficacy of SA14-14-2 against intraperitoneal challenge with different heterologous JE virus
strains. Mice were immunized with either 2340 pfu, 234 pfu or 23 pfu of SA14-14-2 virus;a) Number surviving
challenge/number challenged.
However, since 1970’s, a new genotype I of JEV has circulated in China while the genotype III
JEV are still circulating in nature. In order to further categorize the degree of immunogenici‐
ty conferred by the SA14-14-2 vaccine against the both wild-type JEV genotypes (I and III)
currently circulating in China. Liu et al [32] examined the protective efficacies of the SA14-14-2
live vaccine in mice by a single s.c.vaccination followed by i.p. challenge with 16 JEV iso‐
lates of the both genotype. As shown in Table 15,mice immunized with 2340 pfu of the live
vaccine virus conferred an 80-100% protection rate against challenge with the 16 heterolo‐
gous JE virus strains. Protection efficacy was 70-80% with vaccination dose as low as 234 pfu.
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This result was consistent with previous data indicating SA14-14-2 vaccine conferred strong
and broad protections against JEV challenge[59][21].
4.3. Suppression of viremia induction
As shown in Table 16, guinea-pigs immunized with a single SA14-14-2 dose of 5.87 pfu/mL
virus induced low neutralizing antibody levels(<10 by PRNT) 14 days after vaccination, but
viremia was significantly suppressed in all vaccinated animals after i.p. challenge with P3
virulent JE strain compared to control animals in which all developed high levels of viremia
(2.0-3.54log10 pfu/mL) that last 4 days. Interestingly, despite the neutralizing antibody levels
of the vaccinated animals at the day of challenge (day0) were low, higher levels antibody
developed rapidly beginning at day 4 post challenge compared to the control animals that
developed slowly with low level antibodies beginning at day 7 post challenge [19].
Vaccine No.
testing
Viremia by day after challenge Titer of N antibody by day after challenge
2 3 4 5 7 0 2 3 4 5 7 14
SA14-14-2 1 0/2a ND ND 0/2 0/2 <4-4c <4-4 ND ND 256 1024 2048
2 0/3 0/3 0/3 ND 0/3 <4-16 <4-16 <4-16 16-6
4
ND 128-1024 1024-204
8
None
(control)
1 3/3
(2.1-2.8)b
ND ND 0/3 0/3 < 4 < 4 ND ND <4 <4-8 32-64
2 4/4
(2.0-2.7)
4/4
(1.7-2.8)
2/2
(1.0-1.7)
ND 0/4 < 4 < 4 < 4 < 4 ND 8 128
Table 16. Viremia suppression in guinea-pigs after vaccination with SA14-14-2 vaccine followed by challenge with
virulent JEV. a, No. viremia positive/ no. tested; b,Viremia titre,log10 pfu/mL; c, Reciprocal of the highest dilution of
serum that resulted in 50% reduction of plaque numbers
4.4. Evidence of cellular immune responses
Several studies have shown evidence of cellular immunity induced by vaccination of
SA14-14-2 vaccine in mice. Li et al.[28] studied the specific cytotoxic T lymphocyte (CTL)
mediated immune responses in mice by vaccination with SA14-14-2 live vaccine and PHK
inactivated vaccine. In the three testings, the average percentage of the specific CTL activity
induced by mice vaccinated with one dose of live vaccine was higher (79.2%) than the mice
immunized with twice doses of the inactivated vaccine (29.0%). Jia et al. [17] studied adop‐
tive immunity in mice and demonstrated that mice received transfer of immune spleen cells
from mice immunized with SA14-14-2 live vaccine was protected better (50% protection)
than that from mice immunized with 2 doses of inactivated vaccine (10% protection).Anoth‐
er study was performed for examining the elicitation of cellular immunity by SA14-14-2 vac‐
cine using an enzyme-linked immunospot (ELISPOT) assay. BALB/C mice were s.c.
vaccinated with one dose of the live vaccine or 2 doses of a commercial SA14-14-2 inactivat‐
ed PHK vaccine. Fourteen days after the initial immunization, mice were sacrificed and the
the spleenocytes were isolated for detection of INF-฀ and IL-2 spot forming cells (SFC) by
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ELISPOT assay. Serum samples were collected from the mice and pooled for detecting neu‐
tralizing antibody. Another group of immunized mice were i.p. challenged by virulent JEV
P3 strains 14 days postvaccination. The results demonstrated that mice immunized with
SA14-14-2 live vaccine produced more IFN-γ SFC (89/106 cells) and IL-2 SFC (70-100/106
cells) than mice immunized with the inactivated vaccine (<10/106 cells), respectively, the pos‐
itive conversion rates of mice producing IFN-γ and IL-2 SFC following the vaccination with
live vaccine compared to the vaccination with inactivated were significant i.e, 100% and
100% vs 20% and 40% respectively. However, neutralizing antibody levels in mice following
vaccination with the both vaccines were similar, but higher protection effects were observed
for the live vaccine immunized mice (100% vs 80%) (Table 17) [26]. These data suggested the
protection correlated better with cellular immunity than neutralizing antibody responses
following live vaccine vaccination. Moreover, Li et al. [29] investigated the interaction of
SA14-14-2 virus with mouse bone marrow-derived dendritic cells (bmDCs). The results
showed that the infection of bmDCs with SA14-14-2 resulted in viral replication and upre‐
gulation of bmDCs maturation marker molecules(CD40,CD80,CD83 and MHC1). The infec‐
tion also stimulated the production of interferon-α(IFN-α),monocyte chemoattractant
protein-1 (MCP-1/CCL2), tumor necrosis factor-α(TNF-α) and interleukin-6 (IL-6) of
bmDCs. Furthermore, the SA14-14-2 infected bmDCs impaired the expansion of Foxp3+ reg‐
ulatory T (Treg) cells with immunosuppressive potential, suggesting that SA14-14-2 infec‐
tion induced antiviral immunity rather than immunosuppression. Taken together, the
results indicated that SA14-14-2 infection caused bmDCs maturation, changed the expres‐
sion profiles of several cytokines, and triggered T cell activation. This offered an insight in
the immunologic mechanisms associated with the high efficacy of the SA14-14-2 vaccine.
Vaccine Vaccinated dose (log10pfu/ml)
ELISPOT assay Protection NAb
IFN-r IL-2
SA14-14-2
PHK live
6.31 10/10a 10/10b 10/10c 40d
3.31 10/10 10/10 9/10 40
2.31 9/10 10/10 5/10 10
SA14-14-2
inactivated Undiluted 2/10 4/10 8/10 40
Control - 0/10 0/10 0/10 10
Table 17. Results of ELISPOT assay, protections and neutralizing antibody (NAb) responses in mice vaccinated with
SA14-14-2 live and inactivated JE vaccines. a No. IFN-γ positive/no. tested mice; b No. IL-2 positive/no. tested mice; c
No. survival/no. mice tested;d Reciprocal of the highest dilution of serum that resulted in 50% reduction of plaque
numbers
Recently, Zhang et al.[65] investigated cytokine and chemokine responses in humans recipi‐
ents (34 subjects) of SA14-14-2 live attenuated vaccine, the results indicated that levels of in‐
terleukin (IL-8), monocyte chemoattractant protein (MCP)-1, macrophage inflammatory
protein (MIP)-α and MIP-1β were significantly higher in the vaccinees than in a control
group. IL-6 was detectable in 64.7% of vaccinees, but was not detectable in any of the con‐
Development of Japanese Encephalitis Attenuated Live Vaccine Virus SA14-14-2 and its Charcteristics
http://dx.doi.org/10.5772/ 52980
197
trols. Therefore, IL-6, IL-8, MCP-1,MCP-1α and MIP-1β may play important roles in the im‐
mune response to JE live attenuated vaccine in the humans.
Besides Xu et al.[51] reported that mice immunized with SA14-14-2 virus non-structural NS1
protein, which expressed and purified from SA14-14-2 virus NS1 recombinant E.coli BL21
(DE3), were protected against a lethal JEV challenge (50-70% protection). Guinea-pigs vacci‐
nated with the NS1 protein presented with reduced viremia following challenge with viru‐
lent JE virus (Table 18)
Tested groups No. animals Viremia (pfu/ml) by days postchallenge
0 1 3 5 7 10 14
SA14-14-2 NS1 1 0a 0 0 0 0 0 0
2 0 0 0 0 0 0 0
3 0 0 2. 5 0 0 0 0
4 0 7. 5 20 0 0 0 0
5 0 17. 5 145 15 0 0 0
Unimmunized controls 1 0 7. 5 > 579 208 0 0 0
2 0 47. 5 260 0 0 0 0
3 0 22. 5 318 230 2. 5 0 0
4 0 7. 5 225 0 0 0 0
5 0 0 > 750 ND ND ND ND
Table 18. Viremia suppression in guinea pigs vaccinated with SA14-14-2 NS1 protein followed by challenge with
virulent JEV. ND, Not determinedGuinea pigs were intraperitoneally (i.p.) vaccinated with NS1 protein, each 60 ug, at
day 0 and 7 respectively. Fourteen days after the first vaccination, each vaccinated and unvaccinated animal was i.p.
challenged with virulent JEV P3 strain (each 2.5ml).a No virus detected in the undiluted serum
5. Discussion
Japanese encephalitis is a neuroinvasive virus, which is destructive of neural tissue. Loss of
neurovirulence is an important consideration in live JE vaccine development. It is well
known that the mice and Rhesus monkeys are highly sensitive animals for testing neurovir‐
ulence of JE virus. Both were used during development of live JE vaccine. The process of
derivation of the SA14-14-2 strain has demonstrated fine balances between stable neuroat‐
tenuation and immunogenicity.
The principal issue surrounding the clinical application of the SA14-14-2 live virus vaccine
candidate is safety, especially absence of neurovirulence and stable even passage in brain
tissue. During development of the SA14-14-2 strain, it was demonstrated that unstable attenu‐
ated virus clones i.e. SA14-12-1-7 and SA14-12-1-1 could be detected by several passages in
PHK cells or one i.c. mouse passage. Using this method, SA14-14-2 vaccine virus was select‐
ed for its neuroattenuation stability. To ensure vaccine safety, absence of neuroreversion after
one ic passage in suckling mice is required in the quality control for vaccine production.
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Compared with other live attenuated viral strains, SA14-14-2 has the following characteristics:
1. Not temperature sensitive. During the course of attenuation the SA14 parental virus
was cultured at 37°C, while other live vaccine strains were cultured and passaged at
lower temperature (24℃ or 32-35°C);
2. Homogeneity. SA14-14-2 strain exhibits as homogeneous small plaques and is stable af‐
ter several tissue culture passages. The virus strain has been purified by 14 times by a
plaque picking technique. Many licensed live vaccines were developed without clonal
purification, i.e. the yellow fever 17D vaccine or insufficient purification, i.e. polio vac‐
cine strains. It was reported that the yellow fever 17D vaccine and polio Sabin vaccine
virus particles may be heterogeneous [36, 40], as they were not or insufficient cloned.
The mixtures may contain neurovirulent virus particles;
3. Highly attenuated for experimental animals: SA14-14-2 strain is avirulent following in‐
oculation by intracerebral or subcutaneous routes in 2.5-week old mice. Monkeys inocu‐
lated by the combination of intrathalamic and intraspinal routes developed no signs or
death, and on histopathological examination, exhibited minor inflammatory reaction
only along the needle track. While the yellow fever vaccine strain 17D, in world-wide
use for 70 years, may cause up to 10% death in monkeys while lethal dose in an i.c.
mouse test is as high as 3.0log10LD50. Also, polio vaccine viruses cause more histopa‐
thological lesions in monkeys than did SA14-14-2 virus;
4. Numerous substitutions of nucleotide and amino acid in the virus genome: mutation of
virus genome is the molecular basis of attenuation. Molecular studies indicate that the
SA14-14-2 vaccine strain differs from that of the virulent parental SA14 strain at 57-66
nucleotide locations resulting in 24-31 amino acid changes. The number of mutations
observed is similar to the most stable Polio vaccine virus type I, with 56 nucleotide mu‐
tations resulting in 21 amino acid changes. Polio vaccine virus type III, which is unsta‐
ble, has only 10 nucleotide mutations involving 2-3 amino acids. Polio virus type II, has
23 nucleotide mutations, also fewer than SA14-14-2. More than 70% Vaccine Associated
Paralytic Poliomyelitis has been caused by Type III polio vaccine virus, which has the
fewest amino acid changes from parental virus [40].
As for the immunogenicity of the SA14-14-2 vaccine, studies have demonstrated that protec‐
tion efficacy of the live attenuated vaccine was mediated by the presence of neutralizing an‐
tibodies and by potent cell-mediated immunity as well as the NS1 protein induced
immunity, which associated with the high efficacy of the SA14-14-2 vaccine. Besides anam‐
nestic immune response will give quick rise of neutralizing antibody and provide long-term
protection against JE infection among subjects who become seronegative after immunization
with SA14-14-2 live vaccine [39]
Live JE vaccine (SA14-14-2) has been used in more than 300 million children since large scale
production began in 1989. To date no vaccine associated JE cases has been reported in China
and outside.The safety of live JE vaccine is due to a high degree of neuroattenuation and a
number of stable phenotypic and genotypic characteristics. The combination of lack of vire‐
mia in the vaccinees and the absence of virus replication and dissemination in the mosquito
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vector make the likelihood of transmission of JE vaccine virus and the risk of environment
highly unlikely. Therefore the exceptional safety, stability, immunogenicity and long-term
protective efficacy present a strong case for the expended use of this live attenuated JE vac‐
cine in the world.
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